All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional.

The ALL Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

D-ALBA trial: How can we improve  dasatinib results in  newly diagnosed  Ph+ ALL?

During the EHA2021 Virtual Congress, the ALL Hub spoke with Sabina Chiaretti, Sapienza University of Rome, Rome, IT. We asked, How can we improve dasatinib results in newly diagnosed  Philadelphia chromosome-positive (Ph+) ALL?

D-ALBA trial: How can we improve  dasatinib results in  newly diagnosed  Ph+ ALL?

In this video, Chiaretti discusses the feasibility of improving the results of a chemotherapy-free regimen with dasatinib for patients with newly diagnosed Ph+ ALL.

 

Share: